慢性脫髓鞘多發性神經炎（CIDP）：市場展望、流行病學、競爭格局、市場預測報告（2025-2035年）

市場概覽

• 預計到 2035 年，義大利 CIDP 市場規模將從約 1.45 億美元成長到 3.75 億美元。
• 市場成長受以下因素支撐：
• 擴大靜脈注射免疫球蛋白（IVIG）、皮下注射免疫球蛋白（SCIG）和標靶免疫療法的應用
• 改善診斷技術和長期疾病管理
• 市場擴張是由慢性病治療需求和先進治療方法的日益普及所驅動的。
• 未來的成長取決於新型免疫調節療法和長期疾病管理策略的改進。

慢性脫髓鞘多發性神經炎（CIDP）概述

慢性脫髓鞘多發性神經炎(CIDP) 是一種免疫介導的周邊神經病變，由 T 細胞和自體抗體介導的損傷導致髓鞘形成，引起進行性或復發性近端和遠端肢體無力，並伴隨感覺障礙。患者表現為對稱性肌無力、反射消失、步態不穩和感覺障礙，這些症狀會在數月內逐漸加重。診斷包括去髓鞘化的神經傳導檢查、腦脊髓液細胞和白蛋白分離，以及必要時的神經切片檢查。疾病嚴重程度透過殘障評定量表來評估。糖皮質激素、靜脈注射免疫球蛋白和血漿置換是公認的第一線治療方案，皮下注射免疫球蛋白是一種方便的維持治療方案。皮下注射 fgaltigimod 是一種核准的 FcRn已通過核准治療方案，可減少致病性 IgG 的產生並降低復發風險。治療方案會根據定期的神經學評估結果逐步加強。早期治療和多學科復健有助於維持病情緩解。

主要亮點

• 預計到 2025 年，法國 CIDP 患者人數將增加到約 3,808 人，到 2035 年將增加到 3,992 人。
• CIDP是一種罕見的自體免疫神經系統疾病，其特徵是進行性肌肉無力和感覺障礙。
• 早期診斷和治療對於預防不可逆的神經損傷和功能障礙至關重要。
• 免疫球蛋白療法仍是疾病治療的基石。
• 新型分子標靶免疫療法的出現，正拓展疑難雜症的治療選擇。

格式化和更新訊息

• 詳細報告（PDF）
• 市場預測模型（基於微軟Excel）
• 流行病學數據（MS Excel，互動式工具）
• 高階主管洞察（PPT簡報）
• 其他功能：定期更新、自訂和顧問支援。
• 根據 Thelansis 的政策，我們確保所有最新更新在發布前都反映在報告內容和市場模型中。

主要問題

• 我們如何最佳化 G8 市場（美國、歐盟 5 國、日本、中國）的藥物開發與生命週期管理策略？
• 從發病率、盛行率、人群組成以及接受藥物治療的患者人數來看，患者數量分別是多少？
• 未來十年市場收入和病患佔有率的預測是多少？
• 哪些因素對市場趨勢影響最大？
• 受訪專家對目前和新興的治療方法有何看法？
• 哪款在研發線產品最有前景？其上市潛力及未來市場定位如何？
• 主要未被滿足的需求是什麼？ KOL 對目標受眾有何期望？
• 為確保藥物獲得批准並順利進入市場，必須滿足哪些關鍵的監管和支付方要求？

目標國家

• G8
  • 美國
  • EU5
    • 法國
    • 德國
    • 義大利
    • 西班牙
    • 英國
  • 日本
  • 中國

大公司

• Takeda
• Kine Sciences Co., Ltd.
• Immunovant Sciences GmbH
• Argenx
• Grifols Therapeutics LLC
• Nuvig Therapeutics, Inc.
• Sanofi
• Kite, A Gilead Company
• Janssen Research &Development, LLC
• Kedrion SpA

目錄

第1章：主要調查結果及分析師說明

• 主要趨勢：市場概況、SWOT分析、商業性利益與風險等。

第2章：疾病背景

• 疾病定義、分類、病因和病理生理學、藥物標靶等。

第3章：流行病學

• 重點
• 發病率/盛行率
• 已確診並接受藥物治療的患者人數
• 合併症
• 其他相關患者群

第4章 市場規模及預測

• 重點
• 市場促進因素與限制因素
• 按藥物類別分類的趨勢
• 各國具體趨勢

第5章 競爭情勢

• 目前的治療方法
• 重點
• 診斷和治療過程/演算法
• 主要治療方法概述及KOL洞察
• 新興治療方法
• 重點
• 值得關注的後期新興治療方法—概述、市場上市預期以及KOL洞察。
• 值得關注的早期管道

第6章：未滿足的需求與目標產品分析

• 主要未滿足的需求及其未來透過新興治療方法實現的可能性
• TPP分析與KOL展望

第7章 監理與報銷環境

第8章附錄

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Outlook

Thelansis's "Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report - 2025 To 2035" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Chronic Inflammatory Demyelinating Polyneuropathy treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Overview

Chronic Inflammatory Demyelinating Polyneuropathy is an immune-mediated peripheral neuropathy driven by T-cell and autoantibody-mediated myelin destruction, causing progressive or relapsing proximal and distal limb weakness with sensory impairment. Patients present with symmetric weakness, areflexia, gait instability, and sensory disturbance evolving over months. Diagnosis combines nerve conduction studies showing demyelination, CSF cytoalbuminous dissociation, and nerve biopsy when indicated; disability scales reflect severity. Corticosteroids, intravenous immunoglobulin, and plasma exchange are established first-line treatments; subcutaneous immunoglobulin offers convenient maintenance. Subcutaneous efgartigimod is an approved FcRn-targeted option reducing pathogenic IgG and relapse risk. Regular neurological assessments guide therapy escalation. Early treatment and multidisciplinary rehabilitation support sustained remission.

Key Highlights

• In France, the prevalent CIDP population is projected to increase from approximately 3,808 in 2025 to 3,992 by 2035.
• CIDP is a rare autoimmune neurological disorder characterized by progressive weakness and sensory dysfunction.
• Early diagnosis and treatment remain critical to preventing irreversible nerve damage and disability.
• Immunoglobulin therapy continues to represent the cornerstone of disease management.
• Emerging targeted immunotherapies are expanding treatment options for refractory disease.

Market Overview

• The Italy CIDP market is projected to grow from approximately $145 MN to $375 MN by 2035.
• Market growth is supported by:
• Increasing utilization of IVIG, SCIG, and targeted immunotherapies
• Improved diagnosis and long-term disease management
• Market value growth is driven by chronic treatment requirements and increasing adoption of advanced therapies.
• Future growth will depend on novel immune-modulating therapies and improved long-term disease control strategies.

Insights driven by robust research, including:

• In-depth interviews with leading KOLs and payers
• Physician surveys
• RWE analysis for claims and EHR datasets
• Secondary research (e.g., peer-reviewed journal articles, third-party research databases)

Deliverables format and updates*:

• Detailed Report (PDF)
• Market Forecast Model (MS Excel-based automated dashboard)
• Epidemiology (MS Excel; interactive tool)
• Executive Insights (PowerPoint presentation)
• Others: regular updates, customizations, consultant support
• As per Thelansis's policy, we ensure that we include all the recent updates before releasing the report content and market model.

Salient features of Market Forecast model:

• 10-year market forecast (2025-2035)
• Bottom-up patient-based market forecasts validated through the top-down sales methodology
• Covers clinically and commercially-relevant patient populations/ line of therapies
• Annualized drug-level sales and patient share projections
• Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets and conjoint analysis approach
• Detailed methodology/sources & assumptions
• Graphical and tabular outputs
• Users can customize the model based on requirements

Key business questions answered:

• How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)?
• How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
• What is the 10-year market outlook for sales and patient share?
• Which events will have the greatest impact on the market's trajectory?
• What insights do interviewed experts provide on current and emerging treatments?
• Which pipeline products show the most promise, and what is their potential for launch and future positioning?
• What are the key unmet needs and KOL expectations for target profiles?
• What key regulatory and payer requirements must be met to secure drug approval and favorable market access?

Countries Covered

• G8
  • United States
  • EU5
    • France
    • Germany
    • Italy
    • Spain
    • U.K.
  • Japan
  • China

Apart from the G8 Market, adding any additional country data to the dashboard will cost USD 1,750 per country

Companies Mentioned

• Takeda
• Kine Sciences Co., Ltd.
• Immunovant Sciences GmbH
• Argenx
• Grifols Therapeutics LLC
• Nuvig Therapeutics, Inc.
• Sanofi
• Kite, A Gilead Company
• Janssen Research & Development, LLC
• Kedrion S.p.A.

Table of Contents

1. Key Findings and Analyst Commentary

• Key trends: market snapshots, SWOT analysis, commercial benefits and risks, etc.

2. Disease Context

• Disease definition, classification, etiology and pathophysiology, drug targets, etc.

3. Epidemiology

• Key takeaways
• Incidence / Prevalence
• Diagnosed and Drug-Treated populations
• Comorbidities
• Other relevant patient segments

4. Market Size and Forecast

• Key takeaways
• Market drivers and constraints
• Drug-class specific trends
• Country-specific trends

5. Competitive Landscape

• Current therapies
• Key takeaways
• Dx and Tx journey/algorithm
• Key current therapies - profiles and KOL insights
• Emerging therapies
• Key takeaways
• Notable late-phase emerging therapies - profiles, launch expectations, KOL insights
• Notable early-phase pipeline

6. Unmet Need and TPP Analysis

• Top unmet needs and future attainment by emerging therapies
• TPP analysis and KOL expectations

7. Regulatory and Reimbursement Environments (by country and payer insights)

8. Appendix (e.g., bibliography, methodology)